Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)

NCT05519449 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

272

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostate Cancer
Metastatic Castration-resistant Prostate Cancer
Castration Resistant Prostatic Cancer

Interventions

BIOLOGICAL: JANX007
DRUG: Darolutamide

Sponsor

Janux Therapeutics